Overexpression of Adiponectin Receptors in Opium Users with and without Cancer

References

• Mejía D. The war on drugs under plan Colombia. Rethinking “War on Drugs” Through US-Mexico Prism. 2012;19.
   Google Scholar
• First MB, Gibbon M, Spitzer RL, Williams JB. User’s Guide for the Structured Clinical Interview for DSM-IV Axis I Disorders Research Version. New York: Biometrics Research Department, New York State Psychiatric Institute; 1996.
   Google Scholar
• Chehrazi E, editor Epidemiology of addiction in Iran. Proc 25th Iranian Medical Congress; 1976.
   Google Scholar
• Alemi A, Naraghi M. The iceberg of opium addiction an epidemiological survey of opium addiction in a rural community. Drug Alcohol Depend. 1978;3(2):107–112. doi:10.1016/0376-8716(78)90023-6631011
   PubMed Web of Science ®Google Scholar
• Mee-Lee D. ASAM (American Society of Addiction Medicine) Patient Placement Criteria for the Treatment of Substance-Related Disorders. American Society of Addiction Medicine; 1996.
   Google Scholar
• Narenjiha H, Rafiey H, Jahani MR, Assari S, Moharamzad Y, Roshanpazooh M. Substance-dependent professional drivers in Iran: a descriptive study. Traffic Inj Prev. 2009;10(3):227–230. doi:10.1080/1538958090284901719452363
   PubMed Web of Science ®Google Scholar
• Barber A, Gottschlich R. Opioid agonists and antagonists: an evaluation of their peripheral actions in inflammation. Med Res Rev. 1992;12(5):525–562. doi:10.1002/med.26101205051513187
   PubMed Web of Science ®Google Scholar
• Vuong C, Van Uum SH, O’dell LE, Lutfy K, Friedman TC. The effects of opioids and opioid analogs on animal and human endocrine systems. Endocr Rev. 2009;31(1):98–132.19903933
   PubMed Web of Science ®Google Scholar
• Frenk H. Pro-and anticonvulsant actions of morphine and the endogenous opioids: involvement and interactions of multiple opiate and non-opiate systems. Brain Res Rev. 1983;6(2):197–210. doi:10.1016/0165-0173(83)90039-5
   Google Scholar
• Dhawan B, Cesselin F, Raghubir R, et al. International Union of Pharmacology. XII. Classification of opioid receptors. Pharmacol Rev. 1996;48(4):567–592.8981566
   PubMed Web of Science ®Google Scholar
• La Cava A. Leptin in inflammation and autoimmunity. Cytokine. 2017;98:51–58. doi:10.1016/j.cyto.2016.10.01127916613
   PubMed Web of Science ®Google Scholar
• Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004;89(6):2548–2556. doi:10.1210/jc.2004-039515181022
   PubMed Web of Science ®Google Scholar
• Flier JS, Cook KS, Usher P, Spiegelman BM. Severely impaired adipsin expression in genetic and acquired obesity. Science. 1987;237:405–409. doi:10.1126/science.32997063299706
   PubMed Web of Science ®Google Scholar
• Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPoseMost abundant Gene transcript 1). Biochem Biophys Res Commun. 1996;221(2):286–289. doi:10.1006/bbrc.1996.05878619847
   PubMed Web of Science ®Google Scholar
• Funahashi T, Nakamura T, Shimomura I, et al. 3. Role of adipocytokines on the pathogenesis of atherosclerosis in visceral obesity. Internal Med. 1999;38(2):202–206. doi:10.2169/internalmedicine.38.20210225688
   PubMed Web of Science ®Google Scholar
• Saito K, Tobe T, Minoshima S, et al. Organization of the gene for gelatin-binding protein (GBP28). Gene. 1999;229(1):67–73. doi:10.1016/S0378-1119(99)00041-410095105
   PubMed Web of Science ®Google Scholar
• Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev. 2005;26(3):439–451. doi:10.1210/er.2005-000515897298
   PubMed Web of Science ®Google Scholar
• Takahashi M, Arita Y, Yamagata K, et al. Genomic structure and mutations in adipose-specific gene, adiponectin. Int J Obes. 2000;24(7):861. doi:10.1038/sj.ijo.0801244
   Web of Science ®Google Scholar
• Hug C, Wang J, Ahmad NS, Bogan JS, Tsao T-S, Lodish HF. T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proc Natl Acad Sci U S A. 2004;101(28):10308–10313. doi:10.1073/pnas.040338210115210937
   PubMed Web of Science ®Google Scholar
• Petridou E, Mantzoros C, Dessypris N, et al. Plasma adiponectin concentrations in relation to endometrial cancer: a case-control study in Greece. J Clin Endocrinol Metab. 2003;88(3):993–997. doi:10.1210/jc.2002-02120912629074
   PubMed Web of Science ®Google Scholar
• Soliman PT, Wu D, Tortolero‐Luna G, et al. Association between adiponectin, insulin resistance, and endometrial cancer. Cancer. 2006;106(11):2376–2381.16639730
   PubMed Web of Science ®Google Scholar
• Petridou ET, Mitsiades N, Gialamas S, et al. Circulating adiponectin levels and expression of adiponectin receptors in relation to lung cancer: two case-control studies. Oncology. 2007;73(3–4):261–269. doi:10.1159/00012742418424891
   PubMed Web of Science ®Google Scholar
• Hewer T, Rose E, Ghadirian P, et al. Ingested mutagens from opium and tobacco pyrolysis products and cancer of the oesophagus. Lancet. 1978;312(8088):494–496. doi:10.1016/S0140-6736(78)92218-3
   Google Scholar
• Moossavi S, Mohamadnejad M, Pourshams A, et al. Opium use and risk of pancreatic cancer: a prospective cohort study. Cancer Epidemiol Prev Biomarkers. 2018;27(3):268–273. doi:10.1158/1055-9965.EPI-17-0592
   Web of Science ®Google Scholar
• Kamangar F, Shakeri R, Malekzadeh R, Islami F. Opium use: an emerging risk factor for cancer? Lancet Oncol. 2014;15(2):e69–e77. doi:10.1016/S1470-2045(13)70550-324480557
   PubMed Web of Science ®Google Scholar
• Mahmoodpoor A, Golzari SE. Epigenetics, opium, and cancer. Lancet Oncol. 2014;15(4):e153. doi:10.1016/S1470-2045(14)70077-424694638
   PubMed Web of Science ®Google Scholar
• Alizadeh H, Naghibzadeh Tahami A, Khanjani N, et al. Opium use and head and neck cancers: a matched case-control study in Iran. Asian Pacific J Cancer Prev. 2020;21(3):783–790. doi:10.31557/APJCP.2020.21.3.783
   Google Scholar
• Szczepaniak A, Fichna J, Zielińska M. Opioids in cancer development, progression and metastasis: focus on colorectal cancer. Curr Treat Options Oncol. 2020;21(1):6. doi:10.1007/s11864-019-0699-131970561
   PubMed Web of Science ®Google Scholar
• Ishikawa M, Kitayama J, Yamauchi T, et al. Adiponectin inhibits the growth and peritoneal metastasis of gastric cancer through its specific membrane receptors AdipoR1 and AdipoR2. Cancer Sci. 2007;98(7):1120–1127. doi:10.1111/j.1349-7006.2007.00486.x17459059
   PubMed Web of Science ®Google Scholar
• Hiyoshi M, Tsuno NH, Otani K, et al. Adiponectin receptor 2 is negatively associated with lymph node metastasis of colorectal cancer. Oncol Lett. 2012;3(4):756–760. doi:10.3892/ol.2012.58322740988
   PubMed Web of Science ®Google Scholar
• Dalamaga M, Migdalis I, Fargnoli JL, et al. Pancreatic cancer expresses adiponectin receptors and is associated with hypoleptinemia and hyperadiponectinemia: a case–control study. Cancer Causes Control. 2009;20(5):625–633. doi:10.1007/s10552-008-9273-z19051043
   PubMed Web of Science ®Google Scholar
• Poustchi H, Eghtesad S, Kamangar F, et al. Prospective epidemiological research studies in Iran (the PERSIAN Cohort Study): rationale, objectives, and design. Am J Epidemiol. 2018;187(4):647–655. doi:10.1093/aje/kwx31429145581
   PubMed Web of Science ®Google Scholar
• Yeo C, Saunders N, Locca D, et al. Ficoll-Paque™ versus Lymphoprep™: a comparative study of two density gradient media for therapeutic bone marrow mononuclear cell preparations. Regen Med. 2009;4(5):689–696. doi:10.2217/rme.09.4419761394
   PubMed Web of Science ®Google Scholar
• UNODC W. Opioid Overdose: Preventing and Reducing Opioid Overdose Mortality. Vienna: United Nations Office of Drugs and Crime, World Health Organization; 2013.
   Google Scholar
• Afshari M, Janbabaei G, Bahrami MA, Moosazadeh M. Opium and bladder cancer: A systematic review and meta-analysis of the odds ratios for opium use and the risk of bladder cancer. PLoS One. 2017;12(6):e0178527. doi:10.1371/journal.pone.017852728586371
   PubMed Web of Science ®Google Scholar
• Bakhshaee M, Raziee HR, Afshari R, Amali A, Roopoosh M, Lotfizadeh A. Opium addiction and risk of laryngeal and esophageal carcinoma. Iranian j Otorhinolaryngol. 2017;29(90):19.
   Google Scholar
• Shakeri R, Kamangar F, Mohamadnejad M, et al. Opium use, cigarette smoking, and alcohol consumption in relation to pancreatic cancer. Medicine. 2016;95:28. doi:10.1097/MD.0000000000003922
   Web of Science ®Google Scholar
• Guan G, Zhang D, Zheng Y, et al. microRNA-423-3p promotes tumor progression via modulation of AdipoR2 in laryngeal carcinoma. Int J Clin Exp Pathol. 2014;7(9):5683–5691.25337209
   PubMed Web of Science ®Google Scholar
• Christodoulatos GS, Spyrou N, Kadillari J, Psallida S, Dalamaga M. The role of adipokines in breast cancer: current evidence and perspectives. Curr Obes Rep. 2019;8(4):413–433. doi:10.1007/s13679-019-00364-y31637624
   PubMed Web of Science ®Google Scholar
• Gelsomino L, Naimo GD, Catalano S, Mauro L, Andò S. The emerging role of adiponectin in female malignancies. Int J Mol Sci. 2019;20(9):2127. doi:10.3390/ijms20092127
   Web of Science ®Google Scholar
• Bråkenhielm E, Veitonmäki N, Cao R, et al. Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci U S A. 2004;101(8):2476–2481. doi:10.1073/pnas.030867110014983034
   PubMed Web of Science ®Google Scholar
• Sun G. Adiponectin-AdipoR1 axis in renal cell carcinoma plays a pivotal role in tumor progression and drug resistance. Am Soc Clin Oncol. 2019;37:634. doi:10.1200/JCO.2019.37.7_suppl.634
   Web of Science ®Google Scholar
• Babińska A, Pęksa R, Wiśniewski P, Sworczak K. Expression of adiponectin receptors 1 and 2 and the leptin receptor in human adrenal tumors. Arch Med Sci. 2019;15(5):1254. doi:10.5114/aoms.2018.7614231572471
   PubMed Web of Science ®Google Scholar
• Ramzan AA, Bitler BG, Hicks D, et al. Adiponectin receptor agonist AdipoRon induces apoptotic cell death and suppresses proliferation in human ovarian cancer cells. Mol Cell Biochem. 2019;461(1–2):37–46. doi:10.1007/s11010-019-03586-931292831
   PubMed Web of Science ®Google Scholar
• Govindarajan R, Ratnasinghe L, Simmons DL, et al. Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol. 2007;25(12):1476. doi:10.1200/JCO.2006.07.277717442990
   PubMed Web of Science ®Google Scholar
• MacLennan R, Da Costa J, Day N, Law CH, Ng Y, Shanmugaratnam K. Risk factors for lung cancer in Singapore Chinese, a population with high female incidence rates. Int J cancer. 1977;20(6):854–860. doi:10.1002/ijc.2910200606591126
   PubMed Web of Science ®Google Scholar
• Masjedi MR, Naghan PA, Taslimi S, et al. Opium could be considered an independent risk factor for lung cancer: a case-control study. Respiration. 2013;85(2):112–118. doi:10.1159/00033855922759984
   PubMed Web of Science ®Google Scholar
• Khademi H, Malekzadeh R, Pourshams A, et al. Opium use and mortality in Golestan Cohort Study: prospective cohort study of 50 000 adults in Iran. BMJ. 2012;344:e2502. doi:10.1136/bmj.e250222511302
   PubMed Web of Science ®Google Scholar
• Kubota N, Terauchi Y, Kubota T, et al. Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and-independent pathways. J Biol Chem. 2006;281(13):8748–8755. doi:10.1074/jbc.M50564920016431926
   PubMed Web of Science ®Google Scholar
• Nawrocki AR, Rajala MW, Tomas E, et al. Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to PPARgamma-agonists. J Biol Chem. 2005.
   Web of Science ®Google Scholar
• Folkman J. Tumor angiogenesis In: Advances in Cancer Research. 43 Elsevier; 1985:175–203.2581424
   PubMedGoogle Scholar
• Howard J, Beddy P, Ennis D, Keogan M, Pidgeon G, Reynolds J. Associations between leptin and adiponectin receptor upregulation, visceral obesity and tumour stage in oesophageal and junctional adenocarcinoma. British J Surgery. 2010;97(7):1020–1027. doi:10.1002/bjs.7072
   PubMed Web of Science ®Google Scholar
• Denzel MS, Hebbard LW, Shostak G, Shapiro L, Cardiff RD, Ranscht B. Adiponectin deficiency limits tumor vascularization in the MMTV-PyV-mT mouse model of mammary cancer. Clin Cancer Res. 2009;15(10):3256–3264. doi:10.1158/1078-0432.CCR-08-266119447866
   PubMed Web of Science ®Google Scholar
• Villa NY, Kupchak BR, Garitaonandia I, et al. Sphingolipids function as downstream effectors of a fungal PAQR receptor. Mol Pharmacol. 2008.
   Web of Science ®Google Scholar
• Holland WL, Miller RA, Wang ZV, et al. Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat Med. 2011;17(1):55. doi:10.1038/nm.227721186369
   PubMed Web of Science ®Google Scholar
• Takabe K, Paugh SW, Milstien S, Spiegel S. Inside-out” signaling of sphingosine-1-phosphate: therapeutic targets. Pharmacol Rev. 2008;60:181–195. doi:10.1124/pr.107.0711318552276
   PubMed Web of Science ®Google Scholar
• Landskroner-Eiger S, Qian B, Muise ES, et al. Proangiogenic contribution of adiponectin toward mammary tumor growth in vivo. Clin Cancer Res. 2009;15(10):3265–3276. doi:10.1158/1078-0432.CCR-08-264919447867
   PubMed Web of Science ®Google Scholar
• Dalamaga M, Diakopoulos KN, Mantzoros CS. The role of adiponectin in cancer: a review of current evidence. Endocr Rev. 2012;33(4):547–594. doi:10.1210/er.2011-101522547160
   PubMed Web of Science ®Google Scholar